Get the Stockscreener App
5.99
5.09%
0.29
After Hours:
5.91
-0.08
-1.34%
Organon Co stock is traded at $5.99, with a volume of 3.00M.
It is up +5.09% in the last 24 hours and down -17.83% over the past month.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
See More
Previous Close:
$5.70
Open:
$5.75
24h Volume:
3.00M
Relative Volume:
0.62
Market Cap:
$1.56B
Revenue:
$6.22B
Net Income/Loss:
$187.00M
P/E Ratio:
8.3589
EPS:
0.7166
Net Cash Flow:
$508.00M
1W Performance:
-1.96%
1M Performance:
-17.83%
6M Performance:
-43.91%
1Y Performance:
-59.77%
1-Day Range:
$5.735
$6.015
1-Week Range:
$5.69
$6.285
52-Week Range:
$5.69
$14.90
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
5.99 | 1.48B | 6.22B | 187.00M | 508.00M | 0.7166 |
LLY
Lilly Eli Co
|
919.77 | 792.08B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
244.44 | 584.06B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
217.49 | 376.96B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
197.22 | 300.68B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.29 | 291.99B | 64.93B | 18.26B | 12.36B | 7.2751 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Oct-27-25 | Downgrade | Piper Sandler | Overweight → Underweight |
| May-02-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
Organon (NYSE: OGN) CIO exercises RSUs, 2,809 shares withheld for tax - Stock Titan
Organon (NYSE: OGN) SVP exercises RSUs; 1,516 shares withheld for tax - Stock Titan
Organon (OGN) EVP gains shares via RSU vesting and tax withholding - Stock Titan
[Form 4] Organon & Co. Insider Trading Activity - Stock Titan
Organon (NYSE: OGN) leader nets shares after 5,762 RSUs vest - Stock Titan
Organon (OGN) interim manufacturing chief exercises 7,979 RSUs, nets shares - Stock Titan
Organon (OGN) CMO nets more shares after 8,865 RSUs vest - Stock Titan
Organon (OGN) HR chief converts 8,422 RSUs; 2,885 shares withheld for taxes - Stock Titan
Organon (NYSE: OGN) CFO nets more shares after RSU vesting and tax withholding - Stock Titan
Organon (OGN) interim CEO converts 9,752 RSUs, 2,779 shares withheld for taxes - Stock Titan
Organon & Co stock hits 52-week low at $5.76 By Investing.com - Investing.com Australia
Organon & Co. (OGN) is a trending stock: Facts to know before betting on it - MSN
Organon & Co. (NYSE:OGN) Hits New 12-Month LowHere's What Happened - MarketBeat
Organon & Co. (OGN) Is Gaining Attention: Key Information to Consider Before Investing - Bitget
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Evaluating Organon (OGN) After A Steep Share Price And One Year Return Decline - simplywall.st
Organon & Co Stock: Steady Healthcare Player with Growth Potential Amid Market Pressures - AD HOC NEWS
Organon presents VTAMA cream data for atopic dermatitis at AAD By Investing.com - Investing.com Australia
Organon (OGN) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance Singapore
Organon to present results from Phase 3 Adoring 1, Adoring 2 on Vtama cream - TipRanks
Vanguard disaggregates holdings; reports 0 shares of Organon (OGN) - Stock Titan
Organon & Co. (NYSE:OGN) Receives Consensus Rating of "Reduce" from Brokerages - MarketBeat
Organon presents VTAMA cream data for atopic dermatitis at AAD - Investing.com
Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age - Business Wire
FRA:7XP PB Ratio: 2.12 — 60% Below Median - GuruFocus
Is It Time To Reassess Organon (OGN) After Its Sharp Share Price Slide - simplywall.st
Organon & Co. Stock Plummets to New 52-Week Low of $5.76 - Markets Mojo
Organon & Co stock faces renewed scrutiny amid women's health sector shifts and pipeline updates - AD HOC NEWS
Organon sees opportunities in China's push for high-quality population development - China Daily
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - MSN
Organon: A High Cash Yield Hidden Behind Patent Fatigue - gurufocus.com
Organon & Co. (NYSE:OGN) Hits New 52-Week LowHere's Why - MarketBeat
Organon & Co. Hits New 52-Week Low at USD 6.16 Amidst Declining Performance - Markets Mojo
Assessing Organon (OGN) Valuation After Prolonged Share Price Weakness And A 33% Undervaluation Estimate - simplywall.st
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6? - The Motley Fool
Does a $25 Million Investment in a Stock That Has Fallen 61% Indicate a Possible Recovery at $6? - Bitget
Sio Capital's New Organon Investment: A Value Play in Women's HealthNews and Statistics - IndexBox
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6? - The Motley Fool
Organon leads ultra-low P/E stocks at 1.8x as small-cap stocks face volatility - MSN
Behavioral Patterns of OGN and Institutional Flows - Stock Traders Daily
Organon & Co stock hits 52-week low at 6.17 USD By Investing.com - Investing.com South Africa
Organon & Co stock hits 52-week low at 6.17 USD - Investing.com Australia
Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Organon rises after update on independent review - MSN
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates - GuruFocus
Investors heavily search Organon & Co. (OGN): Here is what you need to know - MSN
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - Yahoo Finance
Aug Wrap: Can Organon Co expand into new marketsWeekly Trade Recap & Reliable Volume Spike Alerts - baoquankhu1.vn
Organon & Co. Experiences Evaluation Revision Amidst Market Challenges and Performance Divergence - Markets Mojo
Gotham Asset Management LLC Buys 1,007,691 Shares of Organon & Co. $OGN - MarketBeat
Organon (OGN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Organon Co Stock (OGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Drinane Juliana Papa | Interim Head of Mfg & Supply |
Nov 07 '25 |
Option Exercise |
0.00 |
3,626 |
0 |
18,417 |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO |
Nov 07 '25 |
Option Exercise |
0.00 |
6,446 |
0 |
31,223 |
| Holzbaur Lynette | SVP and Corporate Controller |
Nov 07 '25 |
Option Exercise |
0.00 |
2,417 |
0 |
15,365 |
| Holzbaur Lynette | SVP and Corporate Controller |
Nov 05 '25 |
Option Exercise |
0.00 |
3,037 |
0 |
13,814 |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO |
Aug 11 '25 |
Option Exercise |
0.00 |
11,519 |
0 |
28,899 |
| COX CARRIE SMITH | Director |
May 14 '25 |
Buy |
8.07 |
12,469 |
100,591 |
12,469 |
| Falcione Aaron | Chief Human Resources Officer |
May 07 '25 |
Buy |
8.77 |
5,500 |
48,235 |
62,974 |
| Weaver Kirke | Gen. Counsel & Corp. Secy. |
May 06 '25 |
Buy |
9.21 |
8,045 |
74,054 |
52,489 |
| Karp Daniel | Executive VP, Corp. Dev. |
May 06 '25 |
Buy |
8.24 |
3,500 |
28,828 |
46,669 |
| WALSH MATTHEW M | Chief Financial Officer |
May 05 '25 |
Buy |
8.82 |
11,400 |
100,548 |
144,484 |
1.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):